Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000002.xml
Aktuelle Dermatologie 2024; 50(01/02): 30-83
DOI: 10.1055/a-2225-7983
DOI: 10.1055/a-2225-7983
Übersicht
S2k-Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa (ICD-10-Code: L73.2)
S2k guideline for the treatment of hidradenitis suppurativa/acne inversa (ICD-10 code L73.2)
Zusammenfassung
Ziel der S2k-Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa (HS/AI) ist es, eine akzeptierte Entscheidungshilfe für die Auswahl sowie Durchführung einer geeigneten/suffizienten Therapie von Patienten mit HS/AI zu liefern. HS/AI ist eine chronisch rezidivierende, entzündliche, potenziell mutilierende Hauterkrankung des terminalen Haartalgdrüsenapparats, die sich mit schmerzhaften, entzündlichen Läsionen in den apokrinen drüsenreichen Körperregionen manifestiert, insbesondere in der axillären sowie der Inguinal- und Anogenitalregion. Die intensive klinische und experimentelle Forschung sowie Überprüfung neuer therapeutischen Ansätze haben seit der Veröffentlichung der alten Leitlinie im Jahr 2012 die Kenntnisse auf dem Gebiet der HS/AI bedeutend verbessert. In Deutschland wurde eine Punktprävalenz der aktiven Erkrankung von 0,3 % beobachtet, sie stieg unter Berücksichtigung von Patienten mit HS/AI-typischen Narben aber nicht aktiver Erkrankung auf 3,0 %. Säulen der HS/AI-Pathogenese sind eine abnormale Differenzierung der Keratinozyten des Haartalgdrüsenapparats und eine massive begleitende Entzündung. Die primären Läsionen der HS/AI sind entzündliche Knoten, Abszesse und drainierende Tunnel, überwiegend an den Prädilektionsstellen (axillär, submammär, inguinal, genital und perineal). Rezidive in den letzten 6 Monaten mit mindestens 2 Läsionen an den Prädilektionsstellen verweisen auf eine HS/AI. Obwohl anhand dieser Kriterien eine klinische Diagnosestellung mit einer hohen Genauigkeit von 97 % erfolgen kann, ist die Erkrankung noch wenig bekannt, wie die Verspätung der Diagnose in Deutschland von 10,0 ± 9,6 Jahren beweist. Patienten mit HS/AI leiden an einer deutlichen Einschränkung der Lebensqualität, insbesondere bei hohem Morbiditätsgrad. HS/AI soll in der täglichen Praxis mit einem validierten Instrument klassifiziert und ihre Aktivität bewertet werden, v. a. mit dem International Hidradenitis Suppurativa Severity Scoring System (IHS4), um korrekte Therapieentscheidungen treffen zu können. Die HS/AI wird in 2 Formen im Zusammenhang mit der Ausprägung der stets nachweisbaren Entzündung eingeteilt, nämlich der entzündlichen und der vorwiegend nicht entzündlichen Formen. Während die Intensität der entzündlichen Form mithilfe der IHS4-Klassifikation in milde, mittelschwere und schwere HS/AI eingeteilt und entsprechend medikamentös behandelt wird, wird für die vorwiegend nicht entzündliche Form über eine chirurgische Behandlung nach dem Hurley-Grad der befallenen Lokalisation, nämlich Hurley-Grad I, II und III entschieden. Orale Tetrazykline oder eine 5-tägige intravenöse Therapie mit Clindamycin sind der Effektivität der oralen systemischen Kombination von Clindamycin und Rifampicin gleich gestellt. Die subkutan applizierbaren monoklonalen Antikörper Adalimumab und Secukinumab sind für die Therapie der HS/AI zugelassen. Für die vorwiegend nicht entzündliche Form der Erkrankung stehen verschiedene operative Verfahren zur Verfügung. Die Kombination einer medikamentösen Therapie zur Reduktion der Entzündung mit einem operativen Verfahren, zur Beseitigung des irreversiblen Gewebeschadens, gilt aktuell als ganzheitliches Therapieverfahren bei HS/AI. Eine regelmäßige Kontrolle und ggf. Anpassung der Therapie im Hinblick auf einen sich ändernden Krankheitsschweregrad wird empfohlen.
Abstract
The aim of the S2k guideline on the therapy of hidradenitis suppurativa/acne inversa (HS/AI) is to provide an accepted decision-making aid for the selection and implementation of a suitable/sufficient therapy for patients with HS/AI. HS/AI is a chronic, relapsing, inflammatory, potentially mutilating skin disease of the terminal pilosebaceous glands that manifests with painful, inflammatory lesions in the apocrine glandular regions of the body, particularly the axillary, inguinal, and anogenital regions. Intensive clinical and experimental research and the review of new therapeutic approaches have almost completely renewed knowledge in the field of HS/AI since the publication of the old guideline in 2012. In Germany, a point prevalence of active disease of 0.3 % was observed, rising to 3.0 % when also taking into account patients with only scars typical of HS/AI. Pillars of HS/AI pathogenesis are abnormal differentiation of the keratinocytes of the pilosebaceous gland and massive accompanying inflammation. The primary lesions of HS/AI are inflammatory nodules, abscesses, and draining tunnels predominantly at predilection sites (axillary, submammary, inguinal, genital, and perineal). Recurrences in the last 6 months with at least 2 lesions at the sites of predilection indicate HS/AI. Although these criteria can be used to make a clinical diagnosis with a high accuracy of 97 %, the disease is still little known, as the delay in diagnosis in Germany of 10.0 ± 9.6 years proves. Patients with HS/AI suffer from a significant reduction in quality of life, especially when there is a high degree of morbidity. In daily practice, HS/AI should be classified and its activity assessed using a validated instrument, primarily using the International Hidradenitis Suppurativa Severity Scoring System (IHS4), in order to be able to make correct treatment decisions. HS/AI is divided into two forms related to the severity of the always detectable inflammation, namely the active, inflammatory and the inactive, predominantly non-inflammatory forms. While the intensity of the inflammatory form is divided into mild, moderate and severe HS/AI using the IHS4 classification and treated accordingly with medications, the predominantly non-inflammatory form is treated surgically according to the Hurley grade of the affected location, namely Hurley-Grade I, II and III. Oral tetracyclines or 5-day intravenous clindamycin therapy are equivalent to the effectiveness of the oral systemic combination of clindamycin and rifampicin. The subcutaneously administered monoclonal antibodies adalimumab and secukinumab are approved for the treatment of HS/AI. Various surgical procedures are available for the predominantly non-inflammatory form of the disease. The combination of drug therapy to reduce inflammation with a surgical procedure to eliminate irreversible tissue damage is currently considered a holistic therapy procedure for HS/AI. Regular monitoring and, if necessary, adjustment of the therapy with regard to a changing degree of disease severity is recommended.
Schlüsselwörter
Hidradenitis suppurativa - Acne inversa - Klassifikation - Schweregrad - Therapie - Leitlinie* Koordination der Delegiertensitzung am 27.04.2023
Publication History
Article published online:
23 February 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Zouboulis CC, Bechara FG, Fritz K. et al. S1-Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa (ICD-10 Ziffer: L73.2). J Dtsch Dermatol Ges 2012; 10 (Suppl. 05) S1-S31 DOI: 10.1111/j.1610-0387.2012.08006.x.
- 2 Lorenz W, Ollenschläger G, Geraedts M. et al. Das Leitlinienmanual von AWMF und ÄZQ. Z Arztl Fortbild Qualitatssich 2001; 95 (Suppl. 01) 1-84
- 3 Just E, Winkler T. Acne inversa: eine seltene Erkrankung mit weitreichenden Auswirkungen für Betroffene. Hautarzt 2021; 72: 715-718 DOI: 10.1007/s00105-021-04861-x.
- 4 Alavi A, Farzanfar D, Rogalska T. et al. Quality of life and sexual health in patients with hidradenitis suppurativa. Int J Womens Dermatol 2018; 4: 74-79 DOI: 10.1016/j.ijwd.2017.10.007.
- 5 Matusiak Ł, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol 2010; 62: 706-708, 708.e1 DOI: 10.1016/j.jaad.2009.09.021.
- 6 Wolkenstein P, Loundou A, Barrau K. et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56: 621-623 DOI: 10.1016/j.jaad.2006.08.061.
- 7 von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001; 144: 809-813 DOI: 10.1046/j.1365-2133.2001.04137.x.
- 8 Kurek A, Peters EMJ, Chanwangpong A. et al. Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol 2012; 67: 422-428, 428.e1 DOI: 10.1016/j.jaad.2011.10.024.
- 9 Janse IC, Deckers IE, van der Maten AD. et al. Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study. Br J Dermatol 2017; 176: 1042-1047 DOI: 10.1111/bjd.14975.
- 10 Matusiak Ł, Szczęch J, Kaaz K. et al. Clinical Characteristics of Pruritus and Pain in Patients with Hidradenitis Suppurativa. Acta Derm Venereol 2018; 98: 191-194 DOI: 10.2340/00015555-2815.
- 11 Sartorius K, Emtestam L, Jemec GBE. et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161: 831-839 DOI: 10.1111/j.1365-2133.2009.09198.x.
- 12 Onderdijk AJ, van der Zee HH, Esmann S. et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2013; 27: 473-478 DOI: 10.1111/j.1468-3083.2012.04468.x.
- 13 Nielsen RM, Lindsø Andersen P, Sigsgaard V. et al. Pain perception in patients with hidradenitis suppurativa. Br J Dermatol 2020; 182: 166-174 DOI: 10.1111/bjd.17935.
- 14 Montero-Vilchez T, Diaz-Calvillo P, Rodriguez-Pozo J-A. et al. The Burden of Hidradenitis Suppurativa Signs and Symptoms in Quality of Life: Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2021; 18: 6709 DOI: 10.3390/ijerph18136709.
- 15 Smith HS, Chao JD, Teitelbaum J. Painful hidradenitis suppurativa. Clin J Pain 2010; 26: 435-444 DOI: 10.1097/AJP.0b013e3181ceb80c.
- 16 Frings VG, Bauer B, Glöditzsch M. et al. Assessing the psychological burden of patients with hidradenitis suppurativa. Eur J Dermatol 2019; 29: 294-301 DOI: 10.1684/ejd.2019.3552.
- 17 Meixner D, Schneider S, Krause M. et al. Acne inversa. J Dtsch Dermatol Ges 2008; 6: 189-196 DOI: 10.1111/j.1610-0387.2007.06492.x.
- 18 Krajewski PK, Matusiak Ł, von Stebut E. et al. Quality-of-Life Impairment among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study of 1795 Patients. Life (Basel) 2021; 11: 34 DOI: 10.3390/life11010034.
- 19 Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60: 539-561 quiz 562–563 DOI: 10.1016/j.jaad.2008.11.911.
- 20 Esmann S, Jemec GBE. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol 2011; 91: 328-332 DOI: 10.2340/00015555-1082.
- 21 Kaaz K, Szepietowski JC, Matusiak Ł. Influence of Itch and Pain on Sleep Quality in Patients with Hidradenitis Suppurativa. Acta Derm Venereol 2018; 98: 757-761 DOI: 10.2340/00015555-2967.
- 22 Seivright JR, Collier E, Grogan T. et al. Physical and psychosocial comorbidities of pediatric hidradenitis suppurativa: A retrospective analysis. Pediatr Dermatol 2021; 38: 1132-1136 DOI: 10.1111/pde.14765.
- 23 Kirsten N, Frings V, Nikolakis GD. et al. Epidemiologie, Patientenlebensqualität und Behandlungskosten der Hidradenitis suppurativa/Acne inversa. Hautarzt 2021; 72: 651-657 DOI: 10.1007/s00105-021-04851-z.
- 24 Jfri A, Nassim D, O’Brien E. et al. Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-regression Analysis. JAMA Dermatol 2021; 157: 924-931 DOI: 10.1001/jamadermatol.2021.1677.
- 25 Kirsten N, Zander N, Augustin M. Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. Arch Dermatol Res 2021; 313: 95-99 DOI: 10.1007/s00403-020-02065-2.
- 26 Dajnoki Z, Somogyi O, Medgyesi B. et al. Primary alterations during the development of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2022; 36: 462-471 DOI: 10.1111/jdv.17779.
- 27 Zouboulis CC, Nogueira da Costa A, Makrantonaki E. et al. Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2020; 34: 846-861 DOI: 10.1111/jdv.16147.
- 28 Zouboulis VA, Zouboulis KC, Zouboulis CC. Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing-A Molecular Meta-Analysis. Pharmaceutics 2021; 14: 44 DOI: 10.3390/pharmaceutics14010044.
- 29 Zouboulis CC, Del Marmol V, Mrowietz U. et al. Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation. Dermatology 2015; 231: 184-190 DOI: 10.1159/000431175.
- 30 Kokolakis G, Wolk K, Schneider-Burrus S. et al. Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System. Dermatology 2020; 236: 421-430 DOI: 10.1159/000508787.
- 31 Zouboulis CC, Tzellos T, Kyrgidis A. et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 2017; 177: 1401-1409 DOI: 10.1111/bjd.15748.
- 32 Tzellos T, van Straalen KR, Kyrgidis A. et al. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2023; 37: 395-401 DOI: 10.1111/jdv.18632.
- 33 Horváth B, Janse IC, Blok JL. et al. Hurley Staging Refined: A Proposal by the Dutch Hidradenitis Suppurativa Expert Group. Acta Derm Venereol 2017; 97: 412-413 DOI: 10.2340/00015555-2513.
- 34 Zouboulis CC, Bechara FG, Dickinson-Blok JL. et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol 2019; 33: 19-31 DOI: 10.1111/jdv.15233.
- 35 van Straalen KR, Tzellos T, Guillem P. et al. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. J Am Acad Dermatol 2021; 85: 369-378 DOI: 10.1016/j.jaad.2020.12.089.
- 36 Kimball AB, Okun MM, Williams DA. et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med 2016; 375: 422-434 DOI: 10.1056/NEJMoa1504370.
- 37 Kimball AB, Jemec GBE, Alavi A. et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 2023; 401: 747-761 DOI: 10.1016/S0140-6736(23)00022-3.
- 38 Bechara FG, Podda M, Prens EP. et al. Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial. JAMA Surg 2021; 156: 1001-1009 DOI: 10.1001/jamasurg.2021.3655.
- 39 Kurzen H, Kurokawa I, Jemec GBE. et al. What causes hidradenitis suppurativa?. Exp Dermatol 2008; 17: 455-456 discussion 457–472 DOI: 10.1111/j.1600-0625.2008.00712_1.x.
- 40 Zouboulis CC, Benhadou F, Byrd AS. et al. What causes hidradenitis suppurativa? – 15 years after. Exp Dermatol 2020; 29: 1154-1170 DOI: 10.1111/exd.14214.
- 41 Kirsten N, Petersen J, Hagenström K. et al. Epidemiology of hidradenitis suppurativa in Germany – an observational cohort study based on a multisource approach. J Eur Acad Dermatol Venereol 2020; 34: 174-179 DOI: 10.1111/jdv.15940.
- 42 Jemec GBE, Kimball AB. Hidradenitis suppurativa: Epidemiology and scope of the problem. J Am Acad Dermatol 2015; 73: S4-S7 DOI: 10.1016/j.jaad.2015.07.052.
- 43 Ingram JR. The epidemiology of hidradenitis suppurativa. Br J Dermatol 2020; 183: 990-998 DOI: 10.1111/bjd.19435.
- 44 Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35: 191-194 DOI: 10.1016/s0190-9622(96)90321-7.
- 45 Cosmatos I, Matcho A, Weinstein R. et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 2013; 68: 412-419 DOI: 10.1016/j.jaad.2012.07.027.
- 46 Revuz JE, Canoui-Poitrine F, Wolkenstein P. et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 596-601 DOI: 10.1016/j.jaad.2008.06.020.
- 47 Botvid SHC, Storgaard Hove L, Bouazzi D. et al. Hidradenitis Suppurativa Prevalence in Nuuk, Greenland: Physician Validation of a Hidradenitis Suppurativa Questionnaire in a Greenlandic Setting. Acta Derm Venereol 2023; 103: adv00847 DOI: 10.2340/actadv.v103.4410.
- 48 Kurzen H, Schönfelder-Funcke S, Hartschuh W. Surgical treatment of Acne inversa at the University of Heidelberg. coloproctology 2000; 22: 76-80
- 49 Nikolakis G, Karagiannidis I, Vaiopoulos AG. et al. Endokrine Mechanismen bei der Pathophysiologie der Hidradenitis suppurativa. Hautarzt 2020; 71: 762-771 DOI: 10.1007/s00105-020-04679-z.
- 50 Schneider-Burrus S, Lux G, van der Linde K. et al. Hidradenitis suppurativa – prevalence analyses of German statutory health insurance data. J Eur Acad Dermatol Venereol 2021; 35: e32-e35 DOI: 10.1111/jdv.16783.
- 51 Schneider-Burrus S, Tsaousi A, Barbus S. et al. Features Associated With Quality of Life Impairment in Hidradenitis Suppurativa Patients. Front Med (Lausanne) 2021; 8: 676241 DOI: 10.3389/fmed.2021.676241.
- 52 Vazquez BG, Alikhan A, Weaver AL. et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 2013; 133: 97-103 DOI: 10.1038/jid.2012.255.
- 53 Vaiopoulos AG, Nikolakis G, Zouboulis CC. Hidradenitis suppurativa in paediatric patients: a retrospective monocentric study in Germany and review of the literature. J Eur Acad Dermatol Venereol 2020; 34: 2140-2146 DOI: 10.1111/jdv.16520.
- 54 Di Cesare A, Nikolakis G, Kanni T. et al. Identification of clinical features affecting diagnostic delay in paediatric hidradenitis suppurativa: results from a multicentre observational study. Br J Dermatol 2022; 187: 428-430 DOI: 10.1111/bjd.21247.
- 55 Loget J, Saint-Martin C, Guillem P. et al. Errance médicale des patients atteints d’hidradénite suppurée: un problème majeur et persistant. Étude "R-ENS Verneuil". Ann Dermatol Venereol 2018; 145: 331-338 DOI: 10.1016/j.annder.2018.01.043.
- 56 Zouboulis CC, Goyal M, Byrd AS. Hidradenitis suppurativa in skin of colour. Exp Dermatol 2021; 30 (Suppl. 01) 27-30 DOI: 10.1111/exd.14341.
- 57 Zouboulis CC. The socioeconomic burden of hidradenitis suppurativa/acne inversa. Br J Dermatol 2019; 181: 7-8 DOI: 10.1111/bjd.17396.
- 58 Nikolakis G, Kokolakis G, Kaleta K. et al. Pathogenese der Hidradenitis suppurativa/Acne inversa. Hautarzt 2021; 72: 658-665 DOI: 10.1007/s00105-021-04853-x.
- 59 Zouboulis CC, Nogueira da Costa A, Fimmel S. et al. Apocrine glands are bystanders in hidradenitis suppurativa and their involvement is gender specific. J Eur Acad Dermatol Venereol 2020; 34: 1555-1563 DOI: 10.1111/jdv.16264.
- 60 Somogyi O, Dajnoki Z, Szabó L. et al. New Data on the Features of Skin Barrier in Hidradenitis Suppurativa. Biomedicines 2023; 11: 127 DOI: 10.3390/biomedicines11010127.
- 61 Kashyap MP, Khan J, Sinha R. et al. Advances in molecular pathogenesis of hidradenitis suppurativa: Dysregulated keratins and ECM signaling. Semin Cell Dev Biol 2022; 128: 120-129 DOI: 10.1016/j.semcdb.2022.01.006.
- 62 Zouboulis CC, Benhadou F, Byrd AS. et al. What causes hidradenitis suppurativa? – 15 years after. Exp Dermatol 2020; 29: 1154-1170 DOI: 10.1111/exd.14214.
- 63 von Laffert M, Helmbold P, Wohlrab J. et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010; 19: 533-537 DOI: 10.1111/j.1600-0625.2009.00915.x.
- 64 Jemec GB, Gniadecka M. Sebum excretion in hidradenitis suppurativa. Dermatology 1997; 194: 325-328 DOI: 10.1159/000246125.
- 65 Kamp S, Fiehn AM, Stenderup K. et al. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. Br J Dermatol 2011; 164: 1017-1022 DOI: 10.1111/j.1365-2133.2011.10224.x.
- 66 Wolk K, Warszawska K, Hoeflich C. et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol 2011; 186: 1228-1239 DOI: 10.4049/jimmunol.0903907.
- 67 Moran B, Sweeney CM, Hughes R. et al. Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy. J Invest Dermatol 2017; 137: 2389-2395 DOI: 10.1016/j.jid.2017.05.033.
- 68 Byrd AS, Carmona-Rivera C, O’Neil LJ. et al. Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa. Sci Transl Med 2019; 11: eaav5908 DOI: 10.1126/scitranslmed.aav5908.
- 69 Frew JW. Hidradenitis suppurativa is an autoinflammatory keratinization disease: A review of the clinical, histologic, and molecular evidence. JAAD Int 2020; 1: 62-72 DOI: 10.1016/j.jdin.2020.05.005.
- 70 Lowe MM, Naik HB, Clancy S. et al. Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-α therapy. JCI Insight 2020; 5: e139932 139932 DOI: 10.1172/jci.insight.139932.
- 71 Jiang SW, Whitley MJ, Mariottoni P. et al. Hidradenitis Suppurativa: Host-Microbe and Immune Pathogenesis Underlie Important Future Directions. JID Innov 2021; 1: 100001 DOI: 10.1016/j.xjidi.2021.100001.
- 72 Schlapbach C, Hänni T, Yawalkar N. et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2011; 65: 790-798 DOI: 10.1016/j.jaad.2010.07.010.
- 73 van der Zee HH, Laman JD, de Ruiter L. et al. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol 2012; 166: 298-305 DOI: 10.1111/j.1365-2133.2011.10698.x.
- 74 Thomi R, Yerly D, Yawalkar N. et al. Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa. Br J Dermatol 2017; 177: 1358-1366 DOI: 10.1111/bjd.15458.
- 75 Jenei A, Dajnoki Z, Medgyesi B. et al. Apocrine Gland-Rich Skin Has a Non-Inflammatory IL-17-Related Immune Milieu, that Turns to Inflammatory IL-17-Mediated Disease in Hidradenitis Suppurativa. J Invest Dermatol 2019; 139: 964-968 DOI: 10.1016/j.jid.2018.10.020.
- 76 Gulliver W, Zouboulis CC, Prens E. et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord 2016; 17: 343-351 DOI: 10.1007/s11154-016-9328-5.
- 77 Zouboulis CC. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa. Expert Rev Clin Immunol 2016; 12: 1015-1026 DOI: 10.1080/1744666X.2016.1221762.
- 78 Wolk K, Wenzel J, Tsaousi A. et al. Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa. Br J Dermatol 2017; 177: 1385-1393 DOI: 10.1111/bjd.15424.
- 79 Lima AL, Karl I, Giner T. et al. Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa. Br J Dermatol 2016; 174: 514-521 DOI: 10.1111/bjd.14214.
- 80 Navrazhina K, Frew JW, Krueger JG. Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa. Br J Dermatol 2020; 182: 1045-1047 DOI: 10.1111/bjd.18556.
- 81 Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ. et al. Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol 2021; 30 (Suppl. 01) 8-17 DOI: 10.1111/exd.14338.
- 82 Kaleta KP, Nikolakis G, Hossini AM. et al. Metabolic Disorders/Obesity Is a Primary Risk Factor in Hidradenitis Suppurativa: An Immunohistochemical Real-World Approach. Dermatology 2022; 238: 251-259 DOI: 10.1159/000517017.
- 83 Jenei A, Dajnoki Z, Medgyesi B. et al. Apocrine Gland-Rich Skin Has a Non-Inflammatory IL-17-Related Immune Milieu, that Turns to Inflammatory IL-17-Mediated Disease in Hidradenitis Suppurativa. J Invest Dermatol 2019; 139: 964-968 DOI: 10.1016/j.jid.2018.10.020.
- 84 Witte-Händel E, Wolk K, Tsaousi A. et al. The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction. J Invest Dermatol 2019; 139: 1294-1305 DOI: 10.1016/j.jid.2018.11.018.
- 85 Wolk K, Brembach T-C, Šimaitė D. et al. Activity and components of the granulocyte colony-stimulating factor pathway in hidradenitis suppurativa. Br J Dermatol 2021; 185: 164-176 DOI: 10.1111/bjd.19795.
- 86 Hotz C, Boniotto M, Guguin A. et al. Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa. J Invest Dermatol 2016; 136: 1768-1780 DOI: 10.1016/j.jid.2016.04.036.
- 87 Di Caprio R, Balato A, Caiazzo G. et al. IL-36 cytokines are increased in acne and hidradenitis suppurativa. Arch Dermatol Res 2017; 309: 673-678 DOI: 10.1007/s00403-017-1769-5.
- 88 Hessam S, Sand M, Gambichler T. et al. Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop. Br J Dermatol 2018; 178: 761-767 DOI: 10.1111/bjd.16019.
- 89 Kelly G, Hughes R, McGarry T. et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol 2015; 173: 1431-1439 DOI: 10.1111/bjd.14075.
- 90 Blok JL, Li K, Brodmerkel C. et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol 2016; 174: 839-846 DOI: 10.1111/bjd.14338.
- 91 Glatt S, Jemec GBE, Forman S. et al. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial. JAMA Dermatol 2021; 157: 1279-1288 DOI: 10.1001/jamadermatol.2021.2905.
- 92 Schuch A, Fischer T, Boehner A. et al. Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab. Acta Derm Venereol 2018; 98: 151-152 DOI: 10.2340/00015555-2794.
- 93 Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373-384 DOI: 10.1038/ni.1863.
- 94 Dréno B, Khammari A, Brocard A. et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol 2012; 148: 182-186 DOI: 10.1001/archdermatol.2011.315.
- 95 Hunger RE, Surovy AM, Hassan AS. et al. Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C-type lectin receptor. Br J Dermatol 2008; 158: 691-697 DOI: 10.1111/j.1365-2133.2007.08425.x.
- 96 Savva A, Kanni T, Damoraki G. et al. Impact of Toll-like receptor-4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa. Br J Dermatol 2013; 168: 311-317 DOI: 10.1111/bjd.12105.
- 97 Volz T, Kaesler S, Biedermann T. Innate immune sensing 2.0 – from linear activation pathways to fine tuned and regulated innate immune networks. Exp Dermatol 2012; 21: 61-69 DOI: 10.1111/j.1600-0625.2011.01393.x.
- 98 Emelianov VU, Bechara FG, Gläser R. et al. Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa. Br J Dermatol 2012; 166: 1023-1034 DOI: 10.1111/j.1365-2133.2011.10765.x.
- 99 Thomi R, Cazzaniga S, Seyed Jafari SM. et al. Association of Hidradenitis Suppurativa With T Helper 1/T Helper 17 Phenotypes: A Semantic Map Analysis. JAMA Dermatol 2018; 154: 592-595 DOI: 10.1001/jamadermatol.2018.0141.
- 100 Giamarellos-Bourboulis EJ, Platzer M, Karagiannidis I. et al. High Copy Numbers of β-Defensin Cluster on 8p23.1, Confer Genetic Susceptibility, and Modulate the Physical Course of Hidradenitis Suppurativa/Acne Inversa. J Invest Dermatol 2016; 136: 1592-1598 DOI: 10.1016/j.jid.2016.04.021.
- 101 Nikolakis G, Liakou AI, Bonovas S. et al. Bacterial Colonization in Hidradenitis Suppurativa/Acne Inversa: A Cross-sectional Study of 50 Patients and Review of the Literature. Acta Derm Venereol 2017; 97: 493-498 DOI: 10.2340/00015555-2591.
- 102 Nikolakis G, Join-Lambert O, Karagiannidis I. et al. Bacteriology of hidradenitis suppurativa/acne inversa: A review. J Am Acad Dermatol 2015; 73: S12-S18 DOI: 10.1016/j.jaad.2015.07.041.
- 103 Ring HC, Thorsen J, Saunte DM. et al. The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls. JAMA Dermatol 2017; 153: 897-905 DOI: 10.1001/jamadermatol.2017.0904.
- 104 Guet-Revillet H, Coignard-Biehler H, Jais J-P. et al. Bacterial pathogens associated with hidradenitis suppurativa, France. Emerg Infect Dis 2014; 20: 1990-1998 DOI: 10.3201/eid2012.140064.
- 105 Ring HC, Bay L, Nilsson M. et al. Bacterial biofilm in chronic lesions of hidradenitis suppurativa. Br J Dermatol 2017; 176: 993-1000 DOI: 10.1111/bjd.15007.
- 106 Riverain-Gillet É, Guet-Revillet H, Jais J-P. et al. The Surface Microbiome of Clinically Unaffected Skinfolds in Hidradenitis Suppurativa: A Cross-Sectional Culture-Based and 16S rRNA Gene Amplicon Sequencing Study in 60 Patients. J Invest Dermatol 2020; 140: 1847-1855.e6 DOI: 10.1016/j.jid.2020.02.046.
- 107 Schell SL, Schneider AM, Nelson AM. Yin and Yang: A disrupted skin microbiome and an aberrant host immune response in hidradenitis suppurativa. Exp Dermatol 2021; 30: 1453-1470 DOI: 10.1111/exd.14398.
- 108 Williams SC, Frew JW, Krueger JG. A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa. Exp Dermatol 2021; 30: 1388-1397 DOI: 10.1111/exd.14141.
- 109 Ring HC, Thorsen J, Saunte DM. et al. The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls. JAMA Dermatol 2017; 153: 897-905 DOI: 10.1001/jamadermatol.2017.0904.
- 110 Ring HC, Bay L, Nilsson M. et al. Bacterial biofilm in chronic lesions of hidradenitis suppurativa. Br J Dermatol 2017; 176: 993-1000 DOI: 10.1111/bjd.15007.
- 111 Vossen ARJV, van der Zee HH, Tsoi LC. et al. Novel cytokine and chemokine markers of hidradenitis suppurativa reflect chronic inflammation and itch. Allergy 2019; 74: 631-634 DOI: 10.1111/all.13665.
- 112 Chopra D, Arens RA, Amornpairoj W. et al. Innate immunity and microbial dysbiosis in hidradenitis suppurativa – vicious cycle of chronic inflammation. Front Immunol 2022; 13: 960488 DOI: 10.3389/fimmu.2022.960488.
- 113 Moltrasio C, Tricarico PM, Romagnuolo M. et al. Hidradenitis Suppurativa: A Perspective on Genetic Factors Involved in the Disease. Biomedicines 2022; 10: 2039 DOI: 10.3390/biomedicines10082039.
- 114 Fitzsimmons JS, Guilbert PR. A family study of hidradenitis suppurativa. J Med Genet 1985; 22: 367-373 DOI: 10.1136/jmg.22.5.367.
- 115 Schrader AMR, Deckers IE, van der Zee HH. et al. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol 2014; 71: 460-467 DOI: 10.1016/j.jaad.2014.04.001.
- 116 Kjaersgaard Andersen R, Clemmensen SB, Larsen LA. et al. Evidence of gene-gene interaction in hidradenitis suppurativa: a nationwide registry study of Danish twins. Br J Dermatol 2022; 186: 78-85 DOI: 10.1111/bjd.20654.
- 117 van Straalen KR, Prens EP, Willemsen G. et al. Contribution of Genetics to the Susceptibility to Hidradenitis Suppurativa in a Large, Cross-sectional Dutch Twin Cohort. JAMA Dermatol 2020; 156: 1359-1362 DOI: 10.1001/jamadermatol.2020.3630.
- 118 Gao M, Wang P-G, Cui Y. et al. Inversa acne (hidradenitis suppurativa): a case report and identification of the locus at chromosome 1p21.1-1q25.3. J Invest Dermatol 2006; 126: 1302-1306 DOI: 10.1038/sj.jid.5700272.
- 119 Duchatelet S, Miskinyte S, Delage M. et al. Low Prevalence of GSC Gene Mutations in a Large Cohort of Predominantly Caucasian Patients with Hidradenitis Suppurativa. J Invest Dermatol 2020; 140: 2085-2088.e14 DOI: 10.1016/j.jid.2019.10.025.
- 120 Pink AE, Simpson MA, Desai N. et al. Mutations in the γ-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J Invest Dermatol 2012; 132: 2459-2461 DOI: 10.1038/jid.2012.162.
- 121 Wang B, Yang W, Wen W. et al. Gamma-secretase gene mutations in familial acne inversa. Science 2010; 330: 1065 DOI: 10.1126/science.1196284.
- 122 Nassar D, Hugot JP, Wolkenstein P. et al. Lack of association between CARD15 gene polymorphisms and hidradenitis suppurativa: a pilot study. Dermatology 2007; 215: 359 DOI: 10.1159/000107632.
- 123 Frew JW, Navrazhina K. No evidence that impaired Notch signalling differentiates hidradenitis suppurativa from other inflammatory skin diseases. Br J Dermatol 2020; 182: 1042-1043 DOI: 10.1111/bjd.18593.
- 124 Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2010; 2: 9-16 DOI: 10.4161/derm.2.1.12490.
- 125 Gauntner TD. Hormonal, stem cell and Notch signalling as possible mechanisms of disease in hidradenitis suppurativa: a systems-level transcriptomic analysis. Br J Dermatol 2019; 180: 203-204 DOI: 10.1111/bjd.17093.
- 126 Karagiannidis I, Nikolakis G, Sabat R. et al. Hidradenitis suppurativa/Acne inversa: an endocrine skin disorder?. Rev Endocr Metab Disord 2016; 17: 335-341 DOI: 10.1007/s11154-016-9366-z.
- 127 Karagiannidis I, Nikolakis G, Zouboulis CC. Endocrinologic Aspects of Hidradenitis Suppurativa. Dermatol Clin 2016; 34: 45-49 DOI: 10.1016/j.det.2015.08.005.
- 128 Chu C-B, Yang C-C, Tsai S-J. Hidradenitis suppurativa: Disease pathophysiology and sex hormones. Chin J Physiol 2021; 64: 257-265 DOI: 10.4103/cjp.cjp_67_21.
- 129 Seivright JR, Villa NM, Grogan T. et al. Impact of Pregnancy on Hidradenitis Suppurativa Disease Course: A Systematic Review and Meta-Analysis. Dermatology 2022; 238: 260-266 DOI: 10.1159/000517283.
- 130 Phan K, Charlton O, Smith SD. Hidradenitis suppurativa and polycystic ovarian syndrome: Systematic review and meta-analysis. Australas J Dermatol 2020; 61: e28-e33 DOI: 10.1111/ajd.13110.
- 131 Nikolakis G, Kyrgidis A, Zouboulis CC. Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data. Am J Clin Dermatol 2019; 20: 503-513 DOI: 10.1007/s40257-019-00442-w.
- 132 Chu C-B, Yang C-C, Tsai S-J. Hidradenitis suppurativa: Disease pathophysiology and sex hormones. Chin J Physiol 2021; 64: 257-265 DOI: 10.4103/cjp.cjp_67_21.
- 133 Vossen ARJV, van Straalen KR, Prens EP. et al. Menses and pregnancy affect symptoms in hidradenitis suppurativa: A cross-sectional study. J Am Acad Dermatol 2017; 76: 155-156 DOI: 10.1016/j.jaad.2016.07.024.
- 134 Zouboulis CC. The human skin as a hormone target and an endocrine gland. Hormones (Athens) 2004; 3: 9-26 DOI: 10.14310/horm.2002.11109.
- 135 Collier EK, Price KN, Grogan TR. et al. Characterizing perimenstrual flares of hidradenitis suppurativa. Int J Womens Dermatol 2020; 6: 372-376 DOI: 10.1016/j.ijwd.2020.09.002.
- 136 Mortimer PS, Dawber RP, Gales MA. et al. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol 1986; 115: 263-268 DOI: 10.1111/j.1365-2133.1986.tb05740.x.
- 137 Sabat R, Chanwangpong A, Schneider-Burrus S. et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One 2012; 7: e31810 DOI: 10.1371/journal.pone.0031810.
- 138 Shalom G, Freud T, Harman-Boehm I. et al. Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol 2015; 173: 464-470 DOI: 10.1111/bjd.13777.
- 139 Wolk K, Join-Lambert O, Sabat R. Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol 2020; 183: 999-1010 DOI: 10.1111/bjd.19556.
- 140 Nikolakis G, Kaleta KP, Vaiopoulos AG. et al. Phenotypes and Pathophysiology of Syndromic Hidradenitis Suppurativa: Different Faces of the Same Disease? A Systematic Review. Dermatology 2021; 237: 673-697 DOI: 10.1159/000509873.
- 141 Theut Riis P, Saunte DM, Benhadou F. et al. Low and high body mass index in hidradenitis suppurativa patients-different subtypes?. J Eur Acad Dermatol Venereol 2018; 32: 307-312 DOI: 10.1111/jdv.14599.
- 142 Calao M, Wilson JL, Spelman L. et al. Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study. PLoS One 2018; 13: e0200683 DOI: 10.1371/journal.pone.0200683.
- 143 Delany E, Gormley G, Hughes R. et al. A cross-sectional epidemiological study of hidradenitis suppurativa in an Irish population (SHIP). J Eur Acad Dermatol Venereol 2018; 32: 467-473 DOI: 10.1111/jdv.14686.
- 144 Canoui-Poitrine F, Revuz JE, Wolkenstein P. et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009; 61: 51-57 DOI: 10.1016/j.jaad.2009.02.013.
- 145 Boer J, Nazary M, Riis PT. The Role of Mechanical Stress in Hidradenitis Suppurativa. Dermatol Clin 2016; 34: 37-43 DOI: 10.1016/j.det.2015.08.011.
- 146 Hayran Y, Allı N, Yücel Ç. et al. Serum IL-36α, IL-36β, and IL-36γ levels in patients with hidradenitis suppurativa: association with disease characteristics, smoking, obesity, and metabolic syndrome. Arch Dermatol Res 2020; 312: 187-196 DOI: 10.1007/s00403-019-02012-w.
- 147 Gallagher C, Kirthi S, Burke T. et al. Remission of hidradenitis suppurativa after bariatric surgery. JAAD Case Rep 2017; 3: 436-437 DOI: 10.1016/j.jdcr.2017.06.008.
- 148 Sivanand A, Gulliver WP, Josan CK. et al. Weight Loss and Dietary Interventions for Hidradenitis Suppurativa: A Systematic Review. J Cutan Med Surg 2020; 24: 64-72 DOI: 10.1177/1203475419874412.
- 149 Jennings L, Nestor L, Molloy O. et al. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. Br J Dermatol 2017; 177: 858-859 DOI: 10.1111/bjd.15233.
- 150 Knaysi GA, Cosman B, Crikelair GF. Hidradenitis suppurativa. JAMA 1968; 203: 19-22
- 151 Garg A, Papagermanos V, Midura M. et al. Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A. Br J Dermatol 2018; 178: 709-714 DOI: 10.1111/bjd.15939.
- 152 Denny G, Anadkat MJ. The effect of smoking and age on the response to first-line therapy of hidradenitis suppurativa: An institutional retrospective cohort study. J Am Acad Dermatol 2017; 76: 54-59 DOI: 10.1016/j.jaad.2016.07.041.
- 153 König A, Lehmann C, Rompel R. et al. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999; 198: 261-264 DOI: 10.1159/000018126.
- 154 Aparício Martins I, Valente C, Simões Farinha P. et al. Passive smoking and hidradenitis suppurativa: a retrospective analysis. J Eur Acad Dermatol Venereol 2023; 37: e466-e467 DOI: 10.1111/jdv.18702.
- 155 Dessinioti C, Zisimou C, Tzanetakou V. et al. A retrospective institutional study of the association of smoking with the severity of hidradenitis suppurativa. J Dermatol Sci 2017; 87: 206-207 DOI: 10.1016/j.jdermsci.2017.04.006.
- 156 Kromann CB, Deckers IE, Esmann S. et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol 2014; 171: 819-824 DOI: 10.1111/bjd.13090.
- 157 Hana A, Booken D, Henrich C. et al. Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci 2007; 80: 2214-2220 DOI: 10.1016/j.lfs.2007.02.007.
- 158 Kalayciyan A, Orawa H, Fimmel S. et al. Nicotine and biochanin A, but not cigarette smoke, induce anti-inflammatory effects on keratinocytes and endothelial cells in patients with Behçet’s disease. J Invest Dermatol 2007; 127: 81-89 DOI: 10.1038/sj.jid.5700492.
- 159 Proietti E, Rossini S, Grohmann U. et al. Polyamines and Kynurenines at the Intersection of Immune Modulation. Trends Immunol 2020; 41: 1037-1050 DOI: 10.1016/j.it.2020.09.007.
- 160 Stegemann A, Böhm M. Targeting the α7 nicotinic acetylcholine receptor – A novel road towards the future treatment of skin diseases. Exp Dermatol 2020; 29: 924-931 DOI: 10.1111/exd.14173.
- 161 Feyerabend C, Ings RM, Russel MA. Nicotine pharmacokinetics and its application to intake from smoking. Br J Clin Pharmacol 1985; 19: 239-247 DOI: 10.1111/j.1365-2125.1985.tb02637.x.
- 162 Kintz P, Henrich A, Cirimele V. et al. Nicotine monitoring in sweat with a sweat patch. J Chromatogr B Biomed Sci Appl 1998; 705: 357-361 DOI: 10.1016/s0378-4347(97)00551-3.
- 163 Balabanova S, Krupienski M. [Detection of nicotine in eccrine sweat after stimulation of sweat glands during nicotine withdrawal]. Hautarzt 1995; 46: 255-258 DOI: 10.1007/s001050050250.
- 164 Hana A, Booken D, Henrich C. et al. Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci 2007; 80: 2214-2220 DOI: 10.1016/j.lfs.2007.02.007.
- 165 Pavia CS, Pierre A, Nowakowski J. Antimicrobial activity of nicotine against a spectrum of bacterial and fungal pathogens. J Med Microbiol 2000; 49: 675-676 DOI: 10.1099/0022-1317-49-7-675.
- 166 Durmaz R, Tekerekoğlu MS, Kalcioğlu T. et al. Nasal carriage of methicillin-resistant Staphylococcus aureus among smokers and cigarette factory workers. New Microbiol 2001; 24: 143-147
- 167 Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 1999; 140: 90-95 DOI: 10.1046/j.1365-2133.1999.02613.x.
- 168 Kawashima K, Fujii T. The lymphocytic cholinergic system and its biological function. Life Sci 2003; 72: 2101-2109 DOI: 10.1016/s0024-3205(03)00068-7.
- 169 Kurzen H, Wessler I, Kirkpatrick CJ. et al. The non-neuronal cholinergic system of human skin. Horm Metab Res 2007; 39: 125-135 DOI: 10.1055/s-2007-961816.
- 170 Kurzen H, Berger H, Jäger C. et al. Phenotypical and molecular profiling of the extraneuronal cholinergic system of the skin. J Invest Dermatol 2004; 123: 937-949 DOI: 10.1111/j.0022-202X.2004.23425.x.
- 171 Sørensen LT, Nielsen HB, Kharazmi A. et al. Effect of smoking and abstention on oxidative burst and reactivity of neutrophils and monocytes. Surgery 2004; 136: 1047-1053 DOI: 10.1016/j.surg.2004.04.001.
- 172 Cesko E, Korber A, Dissemond J. Smoking and obesity are associated factors in acne inversa: results of a retrospective investigation in 100 patients. Eur J Dermatol 2009; 19: 490-493 DOI: 10.1684/ejd.2009.0710.
- 173 Ju Q, Yu Q, Song N. et al. [Expression of aryl hydrocarbon receptor in human epidermis, hair follicles and sebaceous glands and its significance]. Chin J Dermatol 2011; 44: 761-764
- 174 Hou X-X, Chen G, Hossini AM. et al. Aryl Hydrocarbon Receptor Modulates the Expression of TNF-α and IL-8 in Human Sebocytes via the MyD88-p65NF-κB/p38MAPK Signaling Pathways. J Innate Immun 2019; 11: 41-51 DOI: 10.1159/000491029.
- 175 Bissonnette R, Stein Gold L, Rubenstein DS. et al. Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol 2021; 84: 1059-1067 DOI: 10.1016/j.jaad.2020.10.085.
- 176 Zouboulis C, Brunner M, Lippert U. et al. Hidradenitis suppurativa/Acne inversa: Aktuelles zur Definition, Epidemiologie, Pathogenese, Klassifikation und Evidenz-basierten Therapie. Akt Dermatol 2015; 45: 185-199
- 177 Poli F, Wolkenstein P, Revuz J. Back and face involvement in hidradenitis suppurativa. Dermatology 2010; 221: 137-141 DOI: 10.1159/000315508.
- 178 Benhadou F, Van der Zee HH, Pascual JC. et al. Pilonidal sinus disease: an intergluteal localization of hidradenitis suppurativa/acne inversa: a cross-sectional study among 2465 patients. Br J Dermatol 2019; 181: 1198-1206 DOI: 10.1111/bjd.17927.
- 179 von Laffert M, Stadie V, Ulrich J. et al. Morphology of pilonidal sinus disease: some evidence of its being a unilocalized type of hidradenitis suppurativa. Dermatology 2011; 223: 349-355 DOI: 10.1159/000335373.
- 180 Breuninger H. Therapie des Pilonidalsinus und der Acne inversa. Hautarzt 2004; 55: 254-258 DOI: 10.1007/s00105-004-0698-3.
- 181 Sabat R, Tsaousi A, Ghoreschi K. et al. Sex-disaggregated population analysis in patients with hidradenitis suppurativa. Front Med (Lausanne) 2022; 9: 1028943 DOI: 10.3389/fmed.2022.1028943.
- 182 Danby FW, Jemec GBE, Marsch WC. et al. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol 2013; 168: 1034-1039 DOI: 10.1111/bjd.12233.
- 183 Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990; 122: 763-769 DOI: 10.1111/j.1365-2133.1990.tb06264.x.
- 184 Zouboulis CC, Desai N, Emtestam L. et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015; 29: 619-644 DOI: 10.1111/jdv.12966.
- 185 Nazzaro G, Passoni E, Veraldi S. et al. Lymph node involvement in hidradenitis suppurativa: Ultrasound and color Doppler study of 85 patients. Skin Res Technol 2020; 26: 960-962 DOI: 10.1111/srt.12896.
- 186 Wortsman X, Revuz J, Jemec GBE. Lymph nodes in hidradenitis suppurativa. Dermatology 2009; 219: 22-24 DOI: 10.1159/000213064.
- 187 Menter A. Recognizing and managing comorbidities and complications in hidradenitis suppurativa. Semin Cutan Med Surg 2014; 33: S54-56 DOI: 10.12788/j.sder.0093.
- 188 Yuan JT, Naik HB. Complications of hidradenitis suppurativa. Semin Cutan Med Surg 2017; 36: 79-85 DOI: 10.12788/j.sder.2017.022.
- 189 Micieli R, Alavi A. Lymphedema in patients with hidradenitis suppurativa: a systematic review of published literature. Int J Dermatol 2018; 57: 1471-1480 DOI: 10.1111/ijd.14173.
- 190 Grada AA, Phillips TJ. Lymphedema: Pathophysiology and clinical manifestations. J Am Acad Dermatol 2017; 77: 1009-1020 DOI: 10.1016/j.jaad.2017.03.022.
- 191 Sachdeva M, Mufti A, Zaaroura H. et al. Squamous cell carcinoma arising within hidradenitis suppurativa: a literature review. Int J Dermatol 2021; 60: e459-e465 DOI: 10.1111/ijd.15677.
- 192 Blum FR, Miles JA, Farag SW. et al. Characterizing the immune checkpoint marker profiles of cutaneous squamous cell carcinomas in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2023; 37: e316-e318 DOI: 10.1111/jdv.18598.
- 193 Pena ZG, Sivamani RK, Konia TH. et al. Squamous cell carcinoma in the setting of chronic hidradenitis suppurativa; report of a patient and update of the literature. Dermatol Online J 2015; 21: 13030/qt9q9707dp
- 194 Li Pomi F, Macca L, Motolese A. et al. Neoplastic Implications in Patients Suffering from Hidradenitis Suppurativa under Systemic Treatments. Biomedicines 2021; 9: 1594 DOI: 10.3390/biomedicines9111594.
- 195 Jourabchi N, Fischer AH, Cimino-Mathews A. et al. Squamous cell carcinoma complicating a chronic lesion of hidradenitis suppurativa: a case report and review of the literature. Int Wound J 2017; 14: 435-438 DOI: 10.1111/iwj.12671.
- 196 Chapman S, Delgadillo D, Barber C. et al. Cutaneous squamous cell carcinoma complicating hidradenitis suppurativa: a review of the prevalence, pathogenesis, and treatment of this dreaded complication. Acta Dermatovenerol Alp Pannonica Adriat 2018; 27: 25-28
- 197 Jung JM, Lee KH, Kim Y-J. et al. Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa. JAMA Dermatol 2020; 156: 844-853 DOI: 10.1001/jamadermatol.2020.1422.
- 198 Jedrzejczak MJ, Ingram JR, Lowes MA. et al. Expert Knowledge, Attitudes, and Practices in Management of Hidradenitis Suppurativa Pain. JAMA Dermatol 2021; 157: 464-466 DOI: 10.1001/jamadermatol.2020.5857.
- 199 Helvacı Ö, Güz G, Adışen E. et al. Hidradenitis Suppurativa: a lesser-known cause of AA amyloidosis. Hippokratia 2020; 24: 33-37
- 200 Kridin K, Amber KT, Comaneshter D. et al. Amyloidosis in hidradenitis suppurativa: a cross-sectional study and review of the literature. Clin Exp Dermatol 2020; 45: 565-571 DOI: 10.1111/ced.14186.
- 201 Utrera-Busquets M, Romero-Maté A, Castaño Á. et al. Severe hidradenitis suppurativa complicated by renal AA amyloidosis. Clin Exp Dermatol 2016; 41: 287-289 DOI: 10.1111/ced.12731.
- 202 Ooi XT, Choi E, Han H. et al. The psychosocial burden of hidradenitis suppurativa in Singapore. JAAD Int 2023; 10: 89-94 DOI: 10.1016/j.jdin.2022.10.010.
- 203 Fauconier M, Reguiai Z, Barbe C. et al. Association between hidradenitis suppurativa and spondyloarthritis. Joint Bone Spine 2018; 85: 593-597 DOI: 10.1016/j.jbspin.2017.09.005.
- 204 Rondags A, Arends S, Wink FR. et al. High prevalence of hidradenitis suppurativa symptoms in axial spondyloarthritis patients: A possible new extra-articular manifestation. Semin Arthritis Rheum 2019; 48: 611-617 DOI: 10.1016/j.semarthrit.2018.03.010.
- 205 Almuhanna N, Finstad A, Alhusayen R. Association between Hidradenitis Suppurativa and Inflammatory Arthritis: A Systematic Review and Meta-Analysis. Dermatology 2021; 237: 740-747 DOI: 10.1159/000514582.
- 206 Gomollón F, Dignass A, Annese V. et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis 2017; 11: 3-25 DOI: 10.1093/ecco-jcc/jjw168.
- 207 Chen W-T, Chi C-C. Association of Hidradenitis Suppurativa With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol 2019; 155: 1022-1027 DOI: 10.1001/jamadermatol.2019.0891.
- 208 Tzellos T, Zouboulis CC. Which hidradenitis suppurativa comorbidities should I take into account?. Exp Dermatol 2022; 31 (Suppl. 01) 29-32 DOI: 10.1111/exd.14633.
- 209 Tzellos T, Zouboulis CC, Gulliver W. et al. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol 2015; 173: 1142-1155 DOI: 10.1111/bjd.14024.
- 210 Horissian M, Maczuga S, Kirby JS. et al. Increased risk of alopecia areata for people with hidradenitis suppurativa in a cross-sectional study. J Am Acad Dermatol 2019; 81: 1431-1432 DOI: 10.1016/j.jaad.2019.05.093.
- 211 Reddy S, Orenstein LAV, Strunk A. et al. Incidence of Long-term Opioid Use Among Opioid-Naive Patients With Hidradenitis Suppurativa in the United States. JAMA Dermatol 2019; 155: 1284-1290 DOI: 10.1001/jamadermatol.2019.2610.
- 212 Kjaersgaard Andersen R, Saunte SK, Jemec GBE. et al. Psoriasis as a comorbidity of hidradenitis suppurativa. Int J Dermatol 2020; 59: 216-220 DOI: 10.1111/ijd.14651.
- 213 Lee JH, Kwon HS, Jung HM. et al. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. J Eur Acad Dermatol Venereol 2018; 32: 1784-1790 DOI: 10.1111/jdv.15071.
- 214 Broderick L, Hoffman HM. IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nat Rev Rheumatol 2022; 18: 448-463 DOI: 10.1038/s41584-022-00797-1.
- 215 Garcovich S, Genovese G, Moltrasio C. et al. PASH, PAPASH, PsAPASH, and PASS: The autoinflammatory syndromes of hidradenitis suppurativa. Clin Dermatol 2021; 39: 240-247 DOI: 10.1016/j.clindermatol.2020.10.016.
- 216 Nikolakis G, Kaleta KP, Vaiopoulos AG. et al. Phenotypes and Pathophysiology of Syndromic Hidradenitis Suppurativa: Different Faces of the Same Disease? A Systematic Review. Dermatology 2021; 237: 673-697 DOI: 10.1159/000509873.
- 217 Leuenberger M, Berner J, Di Lucca J. et al. PASS Syndrome: An IL-1-Driven Autoinflammatory Disease. Dermatology 2016; 232: 254-258 DOI: 10.1159/000443648.
- 218 Schneider-Burrus S, Kalus S, Fritz B. et al. The impact of hidradenitis suppurativa on professional life. Br J Dermatol 2023; 188: 122-130 DOI: 10.1093/bjd/ljac027.
- 219 Hamzavi IH, Sundaram M, Nicholson C. et al. Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa. J Am Acad Dermatol 2017; 77: 1038-1046 DOI: 10.1016/j.jaad.2017.07.027.
- 220 Vinding GR, Miller IM, Zarchi K. et al. The prevalence of inverse recurrent suppuration: a population-based study of possible hidradenitis suppurativa. Br J Dermatol 2014; 170: 884-889 DOI: 10.1111/bjd.12787.
- 221 Jemec GB. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol 1988; 119: 345-350 DOI: 10.1111/j.1365-2133.1988.tb03227.x.
- 222 Kromann CB, Ibler KS, Kristiansen VB. et al. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol 2014; 94: 553-557 DOI: 10.2340/00015555-1800.
- 223 Seyed Jafari SM, Knüsel E, Cazzaniga S. et al. A Retrospective Cohort Study on Patients with Hidradenitis Suppurativa. Dermatology 2018; 234: 71-78 DOI: 10.1159/000488344.
- 224 Lyons AB, Zubair R, Kohli I. et al. Preoperative Ultrasound for Evaluation of Hidradenitis Suppurativa. Dermatol Surg 2019; 45: 294-296 DOI: 10.1097/DSS.0000000000001696.
- 225 Martorell A, Giovanardi G, Gomez-Palencia P. et al. Defining Fistular Patterns in Hidradenitis Suppurativa: Impact on the Management. Dermatol Surg 2019; 45: 1237-1244 DOI: 10.1097/DSS.0000000000001916.
- 226 Griffin N, Williams AB, Anderson S. et al. Hidradenitis suppurativa: MRI features in anogenital disease. Dis Colon Rectum 2014; 57: 762-771 DOI: 10.1097/DCR.0000000000000131.
- 227 Zouboulis CC, Nogueira da Costa A, Jemec GBE. et al. Long-Wave Medical Infrared Thermography: A Clinical Biomarker of Inflammation in Hidradenitis Suppurativa/Acne Inversa. Dermatology 2019; 235: 144-149 DOI: 10.1159/000495982.
- 228 Saunte DM, Boer J, Stratigos A. et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 2015; 173: 1546-1549 DOI: 10.1111/bjd.14038.
- 229 Saunte DML, Jemec GBE. Hidradenitis Suppurativa: Advances in Diagnosis and Treatment. JAMA 2017; 318: 2019-2032 DOI: 10.1001/jama.2017.16691.
- 230 Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus. Surgical approach. In: Roenigk RK, Roenigk Jr HH. eds. Dermatologic Surgery – Principles and Practice. New York: Marcel Dekker, Inc; 1996: 623-645
- 231 Chiricozzi A, Faleri S, Franceschini C. et al. AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa. Wounds 2015; 27: 258-264
- 232 Grant A, Gonzalez T, Montgomery MO. et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62: 205-217 DOI: 10.1016/j.jaad.2009.06.050.
- 233 Hessam S, Scholl L, Sand M. et al. A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa. JAMA Dermatol 2018; 154: 330-335 DOI: 10.1001/jamadermatol.2017.5890.
- 234 Goldfarb N, Lowes MA, Butt M. et al. Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment. Br J Dermatol 2021; 184: 905-912 DOI: 10.1111/bjd.19565.
- 235 Garg A, Zema C, Kim K. et al. Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials. Br J Dermatol 2022; 187: 203-210 DOI: 10.1111/bjd.21236.
- 236 Marzano AV, Chiricozzi A, Giovanardi G. et al. Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore. J Eur Acad Dermatol Venereol 2020; 34: 1815-1821 DOI: 10.1111/jdv.16328.
- 237 Kimball AB, Sobell JM, Zouboulis CC. et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol 2016; 30: 989-994 DOI: 10.1111/jdv.13216.
- 238 Kimball AB, Kerdel F, Adams D. et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 2012; 157: 846-855 DOI: 10.7326/0003-4819-157-12-201212180-00004.
- 239 Rondags A, van Straalen KR, van Hasselt JR. et al. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment. Br J Dermatol 2019; 180: 1214-1220 DOI: 10.1111/bjd.17508.
- 240 Sartorius K, Lapins J, Emtestam L. et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 2003; 149: 211-213 DOI: 10.1046/j.1365-2133.2003.05390.x.
- 241 Zouboulis CC, Gulliver W, Ingram J. et al. Endpoints of clinical trials for Hidradenitis Suppurativa: Proceedings of a round-table session. Exp Dermatol 2020; 29 (Suppl. 01) 67-72 DOI: 10.1111/exd.14123.
- 242 Zouboulis CC, Matusiak Ł, Jemec GBE. et al. Inter-rater and intrarater agreement and reliability in clinical staging of hidradenitis suppurativa/acne inversa. Br J Dermatol 2019; 181: 852-854 DOI: 10.1111/bjd.17982.
- 243 Kimball AB, Sundaram M, Banderas B. et al. Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa. J Dermatolog Treat 2018; 29: 152-164 DOI: 10.1080/09546634.2017.1341614.
- 244 Miller I, Lynggaard CD, Lophaven S. et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol 2011; 165: 391-398 DOI: 10.1111/j.1365-2133.2011.10339.x.
- 245 Zouboulis CC. Pain Index: a new prospective hidradenitis suppurativa patient-reported outcome measure instrument. Br J Dermatol 2021; 184: 1203-1204 DOI: 10.1111/bjd.19798.
- 246 Zouboulis CC, Chernyshov PV. Hidradenitis suppurativa-specific, patient-reported outcome measures. J Eur Acad Dermatol Venereol 2021; 35: 1420-1421 DOI: 10.1111/jdv.17306.
- 247 Chiricozzi A, Bettoli V, De Pità O. et al. HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2019; 33: e24-e26 DOI: 10.1111/jdv.15122.
- 248 Peris K, Lo Schiavo A, Fabbrocini G. et al. HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2019; 33: 766-773 DOI: 10.1111/jdv.15425.
- 249 Ingram JR, Hadjieconomou S, Piguet V. Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process. Br J Dermatol 2016; 175: 263-272 DOI: 10.1111/bjd.14475.
- 250 Zouboulis CC, von Stebut E. Hidradenitis suppurativa/Acne inversa: Von „orphan disease“ zu heilbarer entzündlicher Hauterkrankung. Hautarzt 2021; 72: 647-650 DOI: 10.1007/s00105-021-04863-9.
- 251 van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 2010; 63: 475-480 DOI: 10.1016/j.jaad.2009.12.018.
- 252 Mikkelsen PR, Dufour DN, Zarchi K. et al. Recurrence rate and patient satisfaction of CO2 laser evaporation of lesions in patients with hidradenitis suppurativa: a retrospective study. Dermatol Surg 2015; 41: 255-260 DOI: 10.1097/DSS.0000000000000264.
- 253 Hazen PG, Hazen BP. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg 2010; 36: 208-213 DOI: 10.1111/j.1524-4725.2009.01427.x.
- 254 Cuenca-Barrales C, Montero-Vílchez T, Sanchez-Diaz M. et al. Patterns of Surgical Recurrence in Patients with Hidradenitis Suppurativa. Dermatology 2023; 239: 255-261 DOI: 10.1159/000527400.
- 255 Ovadja ZN, Zugaj M, Jacobs W. et al. Recurrence Rates Following Reconstruction Strategies After Wide Excision of Hidradenitis Suppurativa: A Systematic Review and Meta-analysis. Dermatol Surg 2021; 47: e106-e110 DOI: 10.1097/DSS.0000000000002815.
- 256 Riddle A, Westerkam L, Feltner C. et al. Current Surgical Management of Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis. Dermatol Surg 2021; 47: 349-354 DOI: 10.1097/DSS.0000000000002892.
- 257 Ritz JP, Runkel N, Haier J. et al. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis 1998; 13: 164-168 DOI: 10.1007/s003840050159.
- 258 Altmann S, Fansa H, Schneider W. Axillary hidradenitis suppurativa: a further option for surgical treatment. J Cutan Med Surg 2004; 8: 6-10 DOI: 10.1007/s10227-003-0162-5.
- 259 Ellis LZ. Hidradenitis suppurativa: surgical and other management techniques. Dermatol Surg 2012; 38: 517-536 DOI: 10.1111/j.1524-4725.2011.02186.x.
- 260 Lam J, Krakowski AC, Friedlander SF. Hidradenitis suppurativa (acne inversa): management of a recalcitrant disease. Pediatr Dermatol 2007; 24: 465-473 DOI: 10.1111/j.1525-1470.2007.00544.x.
- 261 van Rappard DC, Mooij JE, Mekkes JR. Mild to moderate hidradenitis suppurativa treated with local excision and primary closure. J Eur Acad Dermatol Venereol 2012; 26: 898-902 DOI: 10.1111/j.1468-3083.2011.04203.x.
- 262 van Hattem S, Spoo JR, Horváth B. et al. Surgical treatment of sinuses by deroofing in hidradenitis suppurativa. Dermatol Surg 2012; 38: 494-497 DOI: 10.1111/j.1524-4725.2011.02255.x.
- 263 Haoxiang X, Chengrang L, Baoxi W. et al. Modified abscess drainage in treatment of eight cases with hidradenitis suppurativa in China. Dermatol Surg 2013; 39: 779-783 DOI: 10.1111/dsu.12110.
- 264 Dahmen RA, Gkalpakiotis S, Mardesicova L. et al. Deroofing followed by thorough sinus tract excision: a modified surgical approach for hidradenitis suppurativa. J Dtsch Dermatol Ges 2019; 17: 698-702 DOI: 10.1111/ddg.13875.
- 265 Saylor DK, Brownstone ND, Naik HB. Office-Based Surgical Intervention for Hidradenitis Suppurativa (HS): A Focused Review for Dermatologists. Dermatol Ther (Heidelb) 2020; 10: 529-549 DOI: 10.1007/s13555-020-00391-x.
- 266 Blok JL, Boersma M, Terra JB. et al. Surgery under general anaesthesia in severe hidradenitis suppurativa: a study of 363 primary operations in 113 patients. J Eur Acad Dermatol Venereol 2015; 29: 1590-1597 DOI: 10.1111/jdv.12952.
- 267 Rompel R, Petres J. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 2000; 26: 638-643 DOI: 10.1046/j.1524-4725.2000.00043.x.
- 268 Wollina U, Tilp M, Meseg A. et al. Management of severe anogenital acne inversa (hidradenitis suppurativa). Dermatol Surg 2012; 38: 110-117 DOI: 10.1111/j.1524-4725.2011.02157.x.
- 269 Schmidt SC, Möller J, Schütte H. et al. Surgical Repair of a Traumatic Gastrobronchial Fistula. Am J Case Rep 2022; 23: e938506 DOI: 10.12659/AJCR.938506.
- 270 Calibre C, Bouhanna A, Salmin J-P. et al. Hidrosadénite axillaire: une stratégie thérapeutique en un temps. Ann Chir Plast Esthet 2013; 58: 670-675 DOI: 10.1016/j.anplas.2011.05.004.
- 271 Chen E, Friedman HI. Management of regional hidradenitis suppurativa with vacuum-assisted closure and split thickness skin grafts. Ann Plast Surg 2011; 67: 397-401 DOI: 10.1097/SAP.0b013e3181f77bd6.
- 272 Pearce FB, Richardson KA. Negative pressure wound therapy, staged excision and definitive closure with split-thickness skin graft for axillary hidradenitis suppurativa: a retrospective study. J Wound Care 2017; 26: S36-S42 DOI: 10.12968/jowc.2017.26.Sup1.S36.
- 273 Ge S, Orbay H, Silverman RP. et al. Negative Pressure Wound Therapy with Instillation and Dwell Time in the Surgical Management of Severe Hidradenitis Suppurativa. Cureus 2018; 10: e3319 DOI: 10.7759/cureus.3319.
- 274 Tchero H, Herlin C, Bekara F. et al. Two-stage surgical repair in 31 patients with stage II-III hidradenitis suppurativa. Int J Dermatol 2018; 57: 745-747 DOI: 10.1111/ijd.13969.
- 275 Mehdizadeh A, Hazen PG, Bechara FG. et al. Recurrence of hidradenitis suppurativa after surgical management: A systematic review and meta-analysis. J Am Acad Dermatol 2015; 73: S70-S77 DOI: 10.1016/j.jaad.2015.07.044.
- 276 Harrison BJ, Mudge M, Hughes LE. Recurrence after surgical treatment of hidradenitis suppurativa. Br Med J (Clin Res Ed) 1987; 294: 487-489 DOI: 10.1136/bmj.294.6570.487.
- 277 Bohn J, Svensson H. Surgical treatment of hidradenitis suppurativa. Scand J Plast Reconstr Surg Hand Surg 2001; 35: 305-309 DOI: 10.1080/028443101750523230.
- 278 Tanaka A, Hatoko M, Tada H. et al. Experience with surgical treatment of hidradenitis suppurativa. Ann Plast Surg 2001; 47: 636-642 DOI: 10.1097/00000637-200112000-00010.
- 279 Burney RE. 35-Year Experience with Surgical Treatment of Hidradenitis Suppurativa. World J Surg 2017; 41: 2723-2730 DOI: 10.1007/s00268-017-4091-7.
- 280 Humphries LS, Kueberuwa E, Beederman M. et al. Wide excision and healing by secondary intent for the surgical treatment of hidradenitis suppurativa: A single-center experience. J Plast Reconstr Aesthet Surg 2016; 69: 554-566 DOI: 10.1016/j.bjps.2015.12.004.
- 281 Mandal A, Watson J. Experience with different treatment modules in hidradenitis suppuritiva: a study of 106 cases. Surgeon 2005; 3: 23-26 DOI: 10.1016/s1479-666x(05)80006-x.
- 282 DeFazio MV, Economides JM, King KS. et al. Outcomes After Combined Radical Resection and Targeted Biologic Therapy for the Management of Recalcitrant Hidradenitis Suppurativa. Ann Plast Surg 2016; 77: 217-222 DOI: 10.1097/SAP.0000000000000584.
- 283 Dalrymple JC, Monaghan JM. Treatment of hidradenitis suppurativa with the carbon dioxide laser. Br J Surg 1987; 74: 420 DOI: 10.1002/bjs.1800740535.
- 284 Sherman AI, Reid R. CO2 laser for suppurative hidradenitis of the vulva. J Reprod Med 1991; 36: 113-117
- 285 Lapins J, Marcusson JA, Emtestam L. Surgical treatment of chronic hidradenitis suppurativa: CO2 laser stripping-secondary intention technique. Br J Dermatol 1994; 131: 551-556 DOI: 10.1111/j.1365-2133.1994.tb08559.x.
- 286 Finley EM, Ratz JL. Treatment of hidradenitis suppurativa with carbon dioxide laser excision and second-intention healing. J Am Acad Dermatol 1996; 34: 465-469 DOI: 10.1016/s0190-9622(96)90441-7.
- 287 Lapins J, Sartorius K, Emtestam L. Scanner-assisted carbon dioxide laser surgery: a retrospective follow-up study of patients with hidradenitis suppurativa. J Am Acad Dermatol 2002; 47: 280-285 DOI: 10.1067/mjd.2002.124601.
- 288 Madan V, Hindle E, Hussain W. et al. Outcomes of treatment of nine cases of recalcitrant severe hidradenitis suppurativa with carbon dioxide laser. Br J Dermatol 2008; 159: 1309-1314 DOI: 10.1111/j.1365-2133.2008.08932.x.
- 289 Grimstad Ø, Tzellos T, Dufour DN. et al. Evaluation of medical and surgical treatments for hidradenitis suppurativa using real-life data from the Scandinavian registry (HISREG). J Eur Acad Dermatol Venereol 2019; 33: 1164-1171 DOI: 10.1111/jdv.15353.
- 290 Krasner BD, Hamzavi FH, Murakawa GJ. et al. Dissecting cellulitis treated with the long-pulsed Nd:YAG laser. Dermatol Surg 2006; 32: 1039-1044 DOI: 10.1111/j.1524-4725.2006.32227.x.
- 291 Sehgal VN, Verma P, Sawant S. et al. Contemporary surgical treatment of hidradenitis suppurativa (HS) with a focus on the use of the diode hair laser in a case. J Cosmet Laser Ther 2011; 13: 180-190 DOI: 10.3109/14764172.2011.594066.
- 292 Tierney E, Mahmoud BH, Hexsel C. et al. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol Surg 2009; 35: 1188-1198 DOI: 10.1111/j.1524-4725.2009.01214.x.
- 293 Vossen ARJV, van der Zee HH, Terian M. et al. Laser-Haarentfernung verändert den Krankheitsverlauf bei leichter Hidradenitis suppurativa. J Dtsch Dermatol Ges 2018; 16: 901-903 DOI: 10.1111/ddg.13563_g.
- 294 Abdel Azim AA, Salem RT, Abdelghani R. Combined fractional carbon dioxide laser and long-pulsed neodymium: yttrium-aluminium-garnet (1064 nm) laser in treatment of hidradenitis suppurativa; a prospective randomized intra-individual controlled study. Int J Dermatol 2018; 57: 1135-1144 DOI: 10.1111/ijd.14075.
- 295 Naouri M, Maruani A, Lagrange S. et al. Treatment of hidradenitis suppurativa using a long-pulsed hair removal neodymium:yttrium-aluminium-garnet laser: A multicenter, prospective, randomized, intraindividual, comparative trial. J Am Acad Dermatol 2021; 84: 203-205 DOI: 10.1016/j.jaad.2020.04.117.
- 296 Fabbrocini G, França K, Lotti T. et al. Intralesional Diode Laser 1064 nm for the Treatment of Hidradenitis Suppurativa: A Report of Twenty Patients. Open Access Maced J Med Sci 2018; 6: 31-34 DOI: 10.3889/oamjms.2018.045.
- 297 Suárez Valladares MJ, Eiris Salvado N, Rodríguez Prieto MA. Treatment of hidradenitis suppurativa with intralesional photodynamic therapy with 5-aminolevulinic acid and 630nm laser beam. J Dermatol Sci 2017; 85: 241-246 DOI: 10.1016/j.jdermsci.2016.12.014.
- 298 Paasch U, Zidane M, Baron JM. et al. S2k-Leitlinie: Lasertherapie der Haut. J Dtsch Dermatol Ges 2022; 20: 1248-1270 DOI: 10.1111/ddg.14879_g.
- 299 Fadel MA, Tawfik AA. New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: a single-blind, randomized, comparative study. Clin Exp Dermatol 2015; 40: 116-122 DOI: 10.1111/ced.12459.
- 300 Highton L, Chan W-Y, Khwaja N. et al. Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. Plast Reconstr Surg 2011; 128: 459-466 DOI: 10.1097/PRS.0b013e31821e6fb5.
- 301 Piccolo D, Di Marcantonio D, Crisman G. et al. Unconventional use of intense pulsed light. Biomed Res Int 2014; 2014: 618206 DOI: 10.1155/2014/618206.
- 302 Kaminaka C, Uede M, Matsunaka H. et al. Clinical studies of the treatment of facial atrophic acne scars and acne with a bipolar fractional radiofrequency system. J Dermatol 2015; 42: 580-587 DOI: 10.1111/1346-8138.12864.
- 303 Wilden S, Friis M, Tuettenberg A. et al. Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF). J Dermatolog Treat 2021; 32: 530-537 DOI: 10.1080/09546634.2019.1677842.
- 304 Schultheis M, Staubach P, Nikolakis G. et al. LAight® Therapy Significantly Enhances Treatment Efficacy of 16 Weeks of Topical Clindamycin Solution in Hurley I and II Hidradenitis Suppurativa: Results from Period A of RELIEVE, a Multicenter Randomized, Controlled Trial. Dermatology 2022; 238: 476-486 DOI: 10.1159/000518540.
- 305 Kurzen H, Kurzen M. Secondary prevention of hidradenitis suppurativa. Dermatol Reports 2019; 11: 8243 DOI: 10.4081/dr.2019.8243.
- 306 Frew JW, Hawkes JE, Krueger JG. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. Ther Adv Chronic Dis 2019; 10: 2040622319830646 DOI: 10.1177/2040622319830646.
- 307 Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983; 22: 325-328 DOI: 10.1111/j.1365-4362.1983.tb02150.x.
- 308 Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998; 39: 971-974 DOI: 10.1016/s0190-9622(98)70272-5.
- 309 Fischer AH, Haskin A, Okoye GA. Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2017; 76: 309-313.e2 DOI: 10.1016/j.jaad.2016.08.001.
- 310 Cassano N, Alessandrini G, Mastrolonardo M. et al. Peeling agents: toxicological and allergological aspects. J Eur Acad Dermatol Venereol 1999; 13: 14-23
- 311 Nikolakis G, von Stebut E. Lokale und neue apparative Therapien der milden Hidradenitis suppurativa. Hautarzt 2021; 72: 676-685 DOI: 10.1007/s00105-021-04849-7.
- 312 Boer J, Jemec GBE. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol 2010; 35: 36-40 DOI: 10.1111/j.1365-2230.2009.03377.x.
- 313 Molinelli E, Brisigotti V, Simonetti O. et al. Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1 % in the management of mild-to-moderate hidradenitis suppurativa: A retrospective study. Dermatol Ther 2022; 35: e15439 DOI: 10.1111/dth.15439.
- 314 Docampo-Simón A, Beltrá-Picó I, Sánchez-Pujol MJ. et al. Topical 15 % Resorcinol Is Associated with High Treatment Satisfaction in Patients with Mild to Moderate Hidradenitis Suppurativa. Dermatology 2022; 238: 82-85 DOI: 10.1159/000515450.
- 315 Theut Riis P, Saunte DM, Sigsgaard V. et al. Intense pulsed light treatment for patients with hidradenitis suppurativa: beware treatment with resorcinol. J Dermatolog Treat 2018; 29: 385-387 DOI: 10.1080/09546634.2017.1387226.
- 316 Dicheva-Radev S. Bedenkliche Stoffe und Rezepturen – Hinweise für die ärztliche Verschreibung. Arzneiverordnung in der Praxis. Arzneiverordnung in der Praxis 2018; 45: 92-98
- 317 Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009; 23: 985-998 DOI: 10.1111/j.1468-3083.2009.03356.x.
- 318 Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012; 366: 158-164 DOI: 10.1056/NEJMcp1014163.
- 319 Riis PT, Boer J, Prens EP. et al. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series. J Am Acad Dermatol 2016; 75: 1151-1155 DOI: 10.1016/j.jaad.2016.06.049.
- 320 García-Martínez FJ, Vilarrasa Rull E, Salgado-Boquete L. et al. Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: a multicenter retrospective clinical study. J Dermatolog Treat 2021; 32: 286-290 DOI: 10.1080/09546634.2019.1655524.
- 321 Pasquale TR, Tan JS. Nonantimicrobial effects of antibacterial agents. Clin Infect Dis 2005; 40: 127-135 DOI: 10.1086/426545.
- 322 Sensi P. History of the development of rifampin. Rev Infect Dis 1983; 5 (Suppl. 03) S402-406 DOI: 10.1093/clinids/5.supplement_3.s402.
- 323 Zheng Z, Stewart PS. Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother 2002; 46: 900-903 DOI: 10.1128/AAC.46.3.900-903.2002.
- 324 Van Vlem B, Vanholder R, De Paepe P. et al. Immunomodulating effects of antibiotics: literature review. Infection 1996; 24: 275-291 DOI: 10.1007/BF01743360.
- 325 Scheinfeld N. Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa: a review of rifampin’s effects on bacteria, bacterial biofilms, and the human immune system. Dermatol Online J 2016; 22: 13030/qt85s8s1s8
- 326 Humbert P, Treffel P, Chapuis JF. et al. The tetracyclines in dermatology. J Am Acad Dermatol 1991; 25: 691-697 DOI: 10.1016/0190-9622(91)70255-z.
- 327 Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch Dermatol 1994; 130: 748-752
- 328 Brinkmeier T, Frosch PJ. Orale Antibiotika mit antiinflammatorischer/immunmodulatorischer Wirkung für die Therapie verschiedener Dermatosen. Hautarzt 2002; 53: 456-465 DOI: 10.1007/s00105-001-0334-4.
- 329 Korting HC, Schöllmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol 2009; 22: 287-294 DOI: 10.1159/000235550.
- 330 Papp-Wallace KM, Endimiani A, Taracila MA. et al. Carbapenems: past, present, and future. Antimicrob Agents Chemother 2011; 55: 4943-4960 DOI: 10.1128/AAC.00296-11.
- 331 Bettoli V, Zauli S, Borghi A. et al. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol 2014; 28: 125-126 DOI: 10.1111/jdv.12127.
- 332 Dessinioti C, Zisimou C, Tzanetakou V. et al. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up. Clin Exp Dermatol 2016; 41: 852-857 DOI: 10.1111/ced.12933.
- 333 Yao Y, Jørgensen A-HR, Ring HC. et al. Effectiveness of clindamycin and rifampicin combination therapy in hidradenitis suppurativa: a 6-month prospective study. Br J Dermatol 2021; 184: 552-553 DOI: 10.1111/bjd.19578.
- 334 Mendonça CO, Griffiths CEM. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol 2006; 154: 977-978 DOI: 10.1111/j.1365-2133.2006.07155.x.
- 335 van der Zee HH, Boer J, Prens EP. et al. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 2009; 219: 143-147 DOI: 10.1159/000228337.
- 336 Gener G, Canoui-Poitrine F, Revuz JE. et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology 2009; 219: 148-154 DOI: 10.1159/000228334.
- 337 Albrecht J, Barbaric J, Nast A. Rifampicin alone may be enough: is it time to abandon the classic oral clindamycin-rifampicin combination for hidradenitis suppurativa?. Br J Dermatol 2019; 180: 949-950 DOI: 10.1111/bjd.17422.
- 338 Zeller V, Magreault S, Heym B. et al. Influence of the clindamycin administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study. Clin Microbiol Infect 2021; 27: 1857.e1-1857.e7 DOI: 10.1016/j.cmi.2021.04.017.
- 339 Nikolakis G, Kristandt A, Hauptmann M. et al. Efficacy of short-term intravenous clindamycin prior to oral clindamycin-rifampicin treatment in hidradenitis suppurativa: a retrospective case series. Br J Dermatol 2021; 185: 1270-1272 DOI: 10.1111/bjd.20645.
- 340 Caposiena Caro RD, Cannizzaro MV, Botti E. et al. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations. J Am Acad Dermatol 2019; 80: 1314-1321 DOI: 10.1016/j.jaad.2018.11.035.
- 341 Marasca C, Masarà A, Annunziata MC. et al. Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa: a strategy to reduce side-effects, improving patients’ compliance. Br J Dermatol 2019; 180: 949 DOI: 10.1111/bjd.17423.
- 342 Jørgensen A-HR, Yao Y, Thomsen SF. et al. Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study. Int J Dermatol 2021; 60: 785-791 DOI: 10.1111/ijd.15459.
- 343 Caposiena Caro RD, Molinelli E, Brisigotti V. et al. Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation. Clin Exp Dermatol 2021; 46: 96-102 DOI: 10.1111/ced.14388.
- 344 Delaunay J, Villani AP, Guillem P. et al. Oral ofloxacin and clindamycin as an alternative to the classic rifampicin-clindamycin in hidradenitis suppurativa: retrospective analysis of 65 patients. Br J Dermatol 2018; 178: e15-e16 DOI: 10.1111/bjd.15739.
- 345 Join-Lambert O, Coignard H, Jais J-P. et al. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology 2011; 222: 49-58 DOI: 10.1159/000321716.
- 346 Join-Lambert O, Coignard-Biehler H, Jais J-P. et al. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother 2016; 71: 513-520 DOI: 10.1093/jac/dkv361.
- 347 Braunberger TL, Nartker NT, Nicholson CL. et al. Ertapenem – a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa. Int J Dermatol 2018; 57: 1088-1093 DOI: 10.1111/ijd.14036.
- 348 Arowojolu AO, Gallo MF, Lopez LM. et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; CD004425 DOI: 10.1002/14651858.CD004425.pub6.
- 349 Swink SM, Jones-Sheets MA, Sinharoy A. et al. Evaluating Dermatology Residents Combined Oral Contraceptive Pill Prescribing Practices, Knowledge, and Comfort Level in the Management of Acne Vulgaris: A Cross-sectional Survey Study. J Clin Aesthet Dermatol 2023; 16: 47-50
- 350 Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol 2002; 119: 992-1007 DOI: 10.1046/j.1523-1747.2002.00613.x.
- 351 Zouboulis CC, Rabe T. [Hormonal antiandrogens in acne treatment]. J Dtsch Dermatol Ges 2010; 8 (Suppl. 01) S60-74 DOI: 10.1111/j.1610-0387.2009.07171.x.
- 352 Sawers RS, Randall VA, Ebling FJ. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol 1986; 115: 269-274 DOI: 10.1111/j.1365-2133.1986.tb05741.x.
- 353 Kraft JN, Searles GE. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg 2007; 11: 125-131 DOI: 10.2310/7750.2007.00019.
- 354 Orfanos CE, Zouboulis CC, Almond-Roesler B. et al. Current use and future potential role of retinoids in dermatology. Drugs 1997; 53: 358-388 DOI: 10.2165/00003495-199753030-00003.
- 355 Ruzicka T, Larsen FG, Galewicz D. et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol 2004; 140: 1453-1459 DOI: 10.1001/archderm.140.12.1453.
- 356 Soria A, Canoui-Poitrine F, Wolkenstein P. et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients’ outcome assessment. Dermatology 2009; 218: 134-135 DOI: 10.1159/000182261.
- 357 Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol 1999; 40: 73-76 DOI: 10.1016/s0190-9622(99)70530-x.
- 358 Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer?. Br J Dermatol 2011; 164: 170-175 DOI: 10.1111/j.1365-2133.2010.10071.x.
- 359 Hogan DJ, Light MJ. Successful treatment of hidradenitis suppurativa with acitretin. J Am Acad Dermatol 1988; 19: 355-356 DOI: 10.1016/s0190-9622(88)80251-2.
- 360 Scheman AJ. Nodulocystic acne and hidradenitis suppurativa treated with acitretin: a case report. Cutis 2002; 69: 287-288
- 361 Matusiak L, Bieniek A, Szepietowski JC. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients. Br J Dermatol 2014; 171: 170-174 DOI: 10.1111/bjd.12884.
- 362 Verdolini R, Simonacci F, Menon S. et al. Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age. G Ital Dermatol Venereol 2015; 150: 155-162
- 363 Gollnick HP, Dümmler U. Retinoids. Clin Dermatol 1997; 15: 799-810 DOI: 10.1016/s0738-081x(97)00013-8.
- 364 Solymár M, Ivic I, Pótó L. et al. Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly – A meta-analysis. PLoS One 2018; 13: e0207947 DOI: 10.1371/journal.pone.0207947.
- 365 Chang J-E, Choi MS. A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders. Int J Mol Sci 2020; 21: 8960 DOI: 10.3390/ijms21238960.
- 366 Zhou Z, Tang Y, Jin X. et al. Metformin Inhibits Advanced Glycation End Products-Induced Inflammatory Response in Murine Macrophages Partly through AMPK Activation and RAGE/NFκB Pathway Suppression. J Diabetes Res 2016; 2016: 4847812 DOI: 10.1155/2016/4847812.
- 367 Itoi S, Terao M, Murota H. et al. 11β-Hydroxysteroid dehydrogenase 1 contributes to the pro-inflammatory response of keratinocytes. Biochem Biophys Res Commun 2013; 440: 265-270 DOI: 10.1016/j.bbrc.2013.09.065.
- 368 Moussa C, Wadowski L, Price H. et al. Metformin as Adjunctive Therapy for Pediatric Patients With Hidradenitis Suppurativa. J Drugs Dermatol 2020; 19: 1231-1234 DOI: 10.36849/JDD.2020.5447.
- 369 Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: A case series of five patients. J Dermatolog Treat 2006; 17: 211-213 DOI: 10.1080/09546630600830588.
- 370 Hofer T, Itin PH. Acne inversa. Eine Dapson-sensitive Dermatose. Hautarzt 2001; 52: 989-992 DOI: 10.1007/s001050170015.
- 371 Yazdanyar S, Boer J, Ingvarsson G. et al. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology 2011; 222: 342-346 DOI: 10.1159/000329023.
- 372 Poveda I, Vilarrasa E, Martorell A. et al. Serum Zinc Levels in Hidradenitis Suppurativa: A Case-Control Study. Am J Clin Dermatol 2018; 19: 771-777 DOI: 10.1007/s40257-018-0374-5.
- 373 Brocard A, Knol A-C, Khammari A. et al. Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology 2007; 214: 325-327 DOI: 10.1159/000100883.
- 374 Hessam S, Sand M, Meier NM. et al. Combination of oral zinc gluconate and topical triclosan: An anti-inflammatory treatment modality for initial hidradenitis suppurativa. J Dermatol Sci 2016; 84: 197-202 DOI: 10.1016/j.jdermsci.2016.08.010.
- 375 Wong D, Walsh S, Alhusayen R. Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. J Am Acad Dermatol 2016; 75: 1059-1062 DOI: 10.1016/j.jaad.2016.06.001.
- 376 Gupta AK, Ellis CN, Nickoloff BJ. et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990; 126: 339-350
- 377 Buckley DA, Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med 1995; 88: 289P-290P
- 378 Rose RF, Goodfield MJD, Clark SM. Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin. Clin Exp Dermatol 2006; 31: 154-155 DOI: 10.1111/j.1365-2230.2005.01983.x.
- 379 Anderson MD, Zauli S, Bettoli V. et al. Cyclosporine treatment of severe Hidradenitis suppurativa – A case series. J Dermatolog Treat 2016; 27: 247-250 DOI: 10.3109/09546634.2015.1088128.
- 380 Savage KT, Brant EG, Rosales Santillan M. et al. Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa. Int J Womens Dermatol 2020; 6: 159-163 DOI: 10.1016/j.ijwd.2020.02.007.
- 381 Nazary M, Prens EP, Boer J. Azathioprine lacks efficacy in hidradenitis suppurativa: a retrospective study of nine patients. Br J Dermatol 2016; 174: 639-641 DOI: 10.1111/bjd.14086.
- 382 Vossen ARJV, van Doorn MBA, van der Zee HH. et al. Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. J Am Acad Dermatol 2019; 80: 80-88 DOI: 10.1016/j.jaad.2018.06.046.
- 383 Haslund P, Lee RA, Jemec GBE. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol 2009; 89: 595-600 DOI: 10.2340/00015555-0747.
- 384 Karampetsou MP, Liossis S-NC, Sfikakis PP. TNF-α antagonists beyond approved indications: stories of success and prospects for the future. QJM 2010; 103: 917-928 DOI: 10.1093/qjmed/hcq152.
- 385 Shuja F, Chan CS, Rosen T. Biologic drugs for the treatment of hidradenitis suppurativa: an evidence-based review. Dermatol Clin 2010; 28: 511-521 523–524; quiz 522–523 DOI: 10.1016/j.det.2010.03.012.
- 386 Huang C-H, Huang I-H, Tai C-C. et al. Biologics and Small Molecule Inhibitors for Treating Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis. Biomedicines 2022; 10: 1303 DOI: 10.3390/biomedicines10061303.
- 387 Adams DR, Yankura JA, Fogelberg AC. et al. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol 2010; 146: 501-504 DOI: 10.1001/archdermatol.2010.72.
- 388 van Straalen KR, Ingram JR, Augustin M. et al. New treatments and new assessment instruments for Hidradenitis suppurativa. Exp Dermatol 2022; 31 Suppl 1: 33-39 DOI: 10.1111/exd.14609.
- 389 Zouboulis CC, Nogueira da Costa A. Drug repurposing through drug-gene interaction profiles for hidradenitis suppurativa/acne inversa treatment. J Eur Acad Dermatol Venereol 2021; 35: e251-e254 DOI: 10.1111/jdv.16976.
- 390 Zouboulis CC, Readhead B, Dudley JT. An additional drug repurposing study for hidradenitis suppurativa/acne inversa. Br J Dermatol 2021; 184: 748-750 DOI: 10.1111/bjd.19627.
- 391 Zouboulis CC, von Stebut E. Bedarf von Real-World-klinischen Therapiestudien für die Hidradenitis suppurativa/Acne inversa. Hautarzt 2021; 72: 700-705 DOI: 10.1007/s00105-021-04847-9.
- 392 Zouboulis CC, Okun MM, Prens EP. et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol 2019; 80: 60-69.e2 DOI: 10.1016/j.jaad.2018.05.040.
- 393 Tzellos T, Yang H, Mu F. et al. Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol 2019; 181: 147-154 DOI: 10.1111/bjd.17101.
- 394 Zouboulis CC, Hansen H, Caposiena Caro RD. et al. Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa. Dermatology 2020; 236: 25-30 DOI: 10.1159/000503606.
- 395 Sánchez Martínez EM, Murray G, Alfageme Roldán F. et al. Adalimumab dose intensification in hidradenitis suppurativa: effectiveness and safety results of a multicentre study. Br J Dermatol 2021; 185: 863-865 DOI: 10.1111/bjd.20525.
- 396 Shih T, Lee K, Grogan T. et al. Infliximab in hidradenitis suppurativa: A systematic review and meta-analysis. Dermatol Ther 2022; 35: e15691 DOI: 10.1111/dth.15691.
- 397 Lesage C, Adnot-Desanlis L, Perceau G. et al. Efficacy and tolerance of prolonged infliximab treatment of moderate-to-severe forms of hidradenitis suppurativa. Eur J Dermatol 2012; 22: 640-644 DOI: 10.1684/ejd.2012.1795.
- 398 Ghias MH, Johnston AD, Kutner AJ. et al. High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa. J Am Acad Dermatol 2020; 82: 1094-1101 DOI: 10.1016/j.jaad.2019.09.071.
- 399 Lim SYD, Cheong EC, Oon HH. Management of severe hidradenitis suppurativa with biologic therapy and wide excision. Arch Plast Surg 2019; 46: 272-276 DOI: 10.5999/aps.2018.00339.
- 400 Grau-Pérez M, Rodríguez-Aguilar L, Roustan G. et al. Drug survival of adalimumab biosimilar vs adalimumab originator in hidradenitis suppurativa: Can equivalence be assumed? A retrospective cohort study. J Eur Acad Dermatol Venereol 2023; 37: e678-e680 DOI: 10.1111/jdv.18801.
- 401 Kirsten N, Ohm F, Gehrdau K. et al. Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response-Data from the German HS Registry HSBest. Life (Basel) 2022; 12: 1518 DOI: 10.3390/life12101518.
- 402 Burlando M, Fabbrocini G, Marasca C. et al. Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study. Biomedicines 2022; 10: 2522 DOI: 10.3390/biomedicines10102522.
- 403 Roccuzzo G, Rozzo G, Burzi L. et al. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What’s beyond cost-effectiveness?. Dermatol Ther 2022; 35: e15803 DOI: 10.1111/dth.15803.
- 404 Montero-Vilchez T, Cuenca-Barrales C, Rodriguez-Tejero A. et al. Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa. J Clin Med 2022; 11: 1007 DOI: 10.3390/jcm11041007.
- 405 Glatt S, Jemec GBE, Forman S. et al. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial. JAMA Dermatol 2021; 157: 1279-1288 DOI: 10.1001/jamadermatol.2021.2905.
- 406 Frew JW, Navrazhina K, Grand D. et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study. J Am Acad Dermatol 2020; 83: 1341-1348 DOI: 10.1016/j.jaad.2020.05.007.
- 407 Frew JW, Navrazhina K, Sullivan-Whalen M. et al. Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study. Br J Dermatol 2021; 184: 350-352 DOI: 10.1111/bjd.19478.
- 408 Esme P, Botsali A, Akoglu G. et al. An Anti-Interleukin-17A Monoclonal Antibody, Ixekizumab, in the Treatment of Resistant Hidradenitis Suppurativa: A Case Series. Skin Appendage Disord 2022; 8: 342-345 DOI: 10.1159/000521860.
- 409 van der Zee HH, de Ruiter L, van den Broecke DG. et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011; 164: 1292-1298 DOI: 10.1111/j.1365-2133.2011.10254.x.
- 410 Dinarello CA. Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med 2011; 269: 16-28 DOI: 10.1111/j.1365-2796.2010.02313.x.
- 411 Arnold DD, Yalamanoglu A, Boyman O. Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders. Front Immunol 2022; 13: 888392 DOI: 10.3389/fimmu.2022.888392.
- 412 Tzanetakou V, Kanni T, Giatrakou S. et al. Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial. JAMA Dermatol 2016; 152: 52-59 DOI: 10.1001/jamadermatol.2015.3903.
- 413 Gottlieb A, Natsis NE, Kerdel F. et al. A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain. J Invest Dermatol 2020; 140: 1538-1545.e2 DOI: 10.1016/j.jid.2019.10.024.
- 414 Montero-Vilchez T, Pozo-Román T, Sánchez-Velicia L. et al. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review. J Dermatolog Treat 2022; 33: 348-353 DOI: 10.1080/09546634.2020.1755008.
- 415 Kozera E, Flora A, Frew JW. Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study. J Am Acad Dermatol 2022; 87: 1440-1442 DOI: 10.1016/j.jaad.2022.07.047.
- 416 Ravi M, Trinidad J. Botulinum Toxin in Hidradenitis Suppurativa: A Systematic Review. J Drugs Dermatol 2022; 21: 408-412 DOI: 10.36849/JDD.5747.
- 417 Geoghegan L, Rodrigues R, Harrison CJ. et al. The Use of Botulinum Toxin in the Management of Hidradenitis Suppurativa: A Systematic Review. Plast Reconstr Surg Glob Open 2022; 10: e4660 DOI: 10.1097/GOX.0000000000004660.
- 418 Grimstad Ø, Kvammen BØ, Swartling C. Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study. Am J Clin Dermatol 2020; 21: 741-748 DOI: 10.1007/s40257-020-00537-9.
- 419 Chernyshov PV, Zouboulis CC, Tomas-Aragones L. et al. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol 2019; 33: 1633-1643 DOI: 10.1111/jdv.15519.
- 420 Chernyshov PV, Finlay AY, Tomas-Aragones L. et al. Quality of Life in Hidradenitis Suppurativa: An Update. Int J Environ Res Public Health 2021; 18: 6131 DOI: 10.3390/ijerph18116131.
- 421 Frew JW, Lowes MA, Goldfarb N. et al. Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary. JAMA Dermatol 2021; 157: 449-455 DOI: 10.1001/jamadermatol.2020.5467.